Finding 1076760 (2023-002)

Significant Deficiency
Requirement
AB
Questioned Costs
-
Year
2023
Accepted
2024-09-30

AI Summary

  • Core Issue: There was a significant deficiency in internal controls regarding allowable costs, leading to unallowable expenses charged to the grant.
  • Impacted Requirements: Compliance with 2 CFR Part 200, which outlines the rules for allowable costs under federal awards.
  • Recommended Follow-Up: Management should establish procedures to prevent unallowable costs from being charged to federal grants.

Finding Text

Federal Agency: U.S. Department of Health and Human Services Federal Program Name: The Department of Health and Human Services/Centers for Disease Control and Prevention Assistance Listing Number: 93.323 Federal Award Identification Number and Year: NU50CK000515 - 2021 Pass-Through Agency: State of Washington Department of Health Pass-Through Number: CBO28488-0 Award Period: July 1, 2023 through July 31, 2024 Type of Finding: • Significant Deficiency in Internal Control over Compliance – Allowable Costs • Other Matters Criteria or specific requirement: 2 CFR Part 200 Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards requires compliance with the provisions of allowable costs. Condition: During our testing, we noted one unallowable expenditure being charged back to the grant. Questioned costs: None. Context: During our testing of allowable costs, it was noted that the initial online order notification price was charged to the grant rather than the price on the actual receipt issued after the order was filled. Cause: Administrative error in charging unallowable costs to federal grants. Effect: Unallowable expenses were charged to the grant. Recommendation: We recommend management implement procedures to ensure that unallowable costs are not charged to federal grants. Views of responsible officials: There is no disagreement with the audit finding.

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 500318 2023-002
    Significant Deficiency
  • 500319 2023-003
    Material Weakness
  • 500320 2023-004
    Material Weakness
  • 500321 2023-005
    Material Weakness
  • 500322 2023-006
    Material Weakness
  • 1076761 2023-003
    Material Weakness
  • 1076762 2023-004
    Material Weakness
  • 1076763 2023-005
    Material Weakness
  • 1076764 2023-006
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
93.323 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $1.16M